

CORCEPT THERAPEUTICS INC  
 Form 4  
 July 06, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**WILSON JAMES N**

2. Issuer Name and Ticker or Trading Symbol  
**CORCEPT THERAPEUTICS INC [CORT]**

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
**07/01/2015**

Director  10% Owner  
 Officer (give title below)  Other (specify below)

**C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE**

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**MENLO PARK, CA 94025**

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|----------------------------------------------------|--------------------------------|-------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
| Common stock                    | 01/15/2015                           |                                                    | G <sup>(1)</sup>               | V 122,000 D \$ 0                                                  | 1,579,396                                                                                     | I                                                        | James N. Wilson and Pamela D. Wilson Trust            |
| Common stock                    | 07/01/2015                           |                                                    | M                              | 10,000 A \$ 1.51                                                  | 1,589,396                                                                                     | I                                                        | James N. Wilson and                                   |

|              |                           |  |                  |        |                  |                            |           |   |                                                                          |
|--------------|---------------------------|--|------------------|--------|------------------|----------------------------|-----------|---|--------------------------------------------------------------------------|
| Common stock | 07/01/2015                |  | S                | 10,000 | D                | \$<br>6.0559<br><u>(2)</u> | 1,579,396 | I | Pamela D. Wilson Trust<br><br>James N. Wilson and Pamela D. Wilson Trust |
| Common stock | 07/01/2015 <sup>(3)</sup> |  | S <sup>(3)</sup> | 0      | D <sup>(3)</sup> | \$ 0                       | 901,067   | I | James and Pamela Wilson Family Partners                                  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |                            |
|--------------------------------------------|--------------------------------------------------------|--------------------------------------|----------------------------------------------------|--------------------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------|---------------------------------------------------------------|-------------------------------|----------------------------|
|                                            |                                                        |                                      |                                                    | Code                           | V (A) (D)                                                                               | Date Exercisable                                         | Expiration Date                                               | Title                         | Amount or Number of Shares |
| Stock option                               | \$ 1.51                                                | 07/01/2015                           |                                                    | M                              | 10,000                                                                                  | <u>(4)</u>                                               | 05/18/2017                                                    | Common stock                  | 10,000                     |

## Reporting Owners

| Reporting Owner Name / Address             | Relationships |           |         |       |
|--------------------------------------------|---------------|-----------|---------|-------|
|                                            | Director      | 10% Owner | Officer | Other |
| WILSON JAMES N<br>C/O CORCEPT THERAPEUTICS | X             |           |         |       |

149 COMMONWEALTH DRIVE  
MENLO PARK, CA 94025

## Signatures

/s/ Joseph K. Belanoff, CEO of Corcept Therapeutics Incorporated  
attorney-in-fact

07/04/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares distributed to family members of the Reporting Person.
- (2) Represents the weighted average sale price for the entire number of shares sold. The sale prices ranged from \$6.00 to \$6.11 per share.
- (3) Not applicable as the line item was included to show all other indirect holdings of the Reporting Person.
- (4) Fully exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.